News Briefing channel feed

Spring­Works teams with Dana-Far­ber to test BC­MA com­bo; VBL restarts PhI­II tri­al af­ter FDA clears gene ther­a­py batch­es

4 years ago

EC ap­proves Bio­Marin drug as first treat­ment for chil­dren with com­mon form of dwarfism; Servi­er sN­DA wins ap­proval

4 years ago

Am­neal touts re­sults from Phase III tri­al in Parkin­son's; No­vaRock part­ners on can­cer drug

4 years ago

Chi­nese phar­ma groups part­ner in $150M li­cens­ing deal; Pfiz­er to join law­suit on tar­iffs

4 years ago

Im­muno­core's bis­pe­cif­ic lands speedy re­view with FDA, EMA; Low-pro­file gene ther­a­py play­er grabs $30M

4 years ago

KalVista clears in­ter­na­tion­al reg­u­la­to­ry hur­dles on HAE tri­al; Elix­iron rais­es $27M in Se­ries A

4 years ago

In­sil­i­co finds a new part­ner for AI drug dis­cov­ery; EU launch­es Il­lu­mi­na probe af­ter Grail merg­er close

4 years ago

Philip Mor­ris nabs over 20% of Vec­tura's shares; On­copep­tides drug may be head­ed for ad­comm, CEO says

4 years ago

Sesen Bio tri­al marred by mis­con­duct — re­port; Bris­tol My­ers picks up de­vel­op­ment of AI out­fit's im­munol­o­gy drug

4 years ago

Au­rinia gets two new as­sets in ac­qui­si­tion, li­cens­ing deal; Shorla preps T-cell leukemia drug for com­mer­cial­iza­tion

4 years ago

Can­cer spe­cial­ist Hi­ber­Cell snaps up an­a­lyt­ics, com­pu­ta­tion­al tools in all-stock buy­out; Prax­is re­veals new per­i­menopausal de­pres­sion da­ta

4 years ago

Mus­tang inks a deal for in vi­vo CAR-T tech from the Mayo Clin­ic; How a spilled cup of tea land­ed one biotech $11.7 mil­lion

4 years ago

Pe­ter Thiel-backed ATAI launch­es new Salvia-fo­cused biotech; Pur­due bank­rupt­cy tri­al ex­pect­ed to be­gin to­day — re­port

4 years ago

Pur­due sub­sidiary nabs non-opi­oid drug for pain; Or­biMed backs small biotech's 'su­pe­ri­or' drug

4 years ago

Keytru­da keeps ex­pand­ing with an­oth­er pri­or­i­ty re­view; Medicxi-backed eye drop mak­er wins new fund­ing, re­gion­al deal

4 years ago

Ab­b­Vie hands over $20M for Alzheimer's, Parkin­son's drugs; Au­to­lus boost­ed by a PIM

4 years ago

Sen­ate Dems call to add Medicare drug price ne­go­ti­a­tions to rec­on­cil­i­a­tion bill; Cer­tara signs $310M buy­out of soft­ware com­pa­ny

4 years ago

Celu­lar­i­ty teams up with Aus­tralian biotech to de­vel­op CAR T-cell ther­a­py; For­mer Kin­nate CEO Stephen Kaldor reels in $50M for new biotech

4 years ago

Am­gen may see $3B+ in ad­di­tion­al tax­es; EQRx, Ab­Cellera ink an­ti­body de­vel­op­ment deal

4 years ago

Roche's PD-L1 fran­chise play­er nabs pri­or­i­ty re­view; One of world's first psy­che­delics re­search in­sti­tutes opens in Aus­tralia

4 years ago

FTC pulls re­main­ing case against Ab­b­Vie; New EU clin­i­cal tri­als sys­tem com­ing in 2022; Abing­worth bets big on CymaBay

4 years ago

Top Gilead can­cer re­searcher jumps to a start­up as Dan Chen ex­its; Arde­lyx gets that CRL we've been wait­ing for

4 years ago

Roche nabs pri­or­i­ty re­view for Eylea com­peti­tor; Italy's An­geli­ni eyes CNS, rare dis­ease star­tups with $35M Lu­mi­ra fund

4 years ago

US sells Wu-Tang Clan al­bum to cov­er Shkre­li debt; Or­biMed backs GSK vet­s' Chi­nese start­up

4 years ago
First page Previous page 27282930313233 Next page Last page
A service from the Financial Times